Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $6.04 million. The enterprise value is $6.02 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 2.37 million shares outstanding. The number of shares has increased by 69.51% in one year.
| Current Share Class | 2.37M |
| Shares Outstanding | 2.37M |
| Shares Change (YoY) | +69.51% |
| Shares Change (QoQ) | +15.74% |
| Owned by Insiders (%) | 31.55% |
| Owned by Institutions (%) | 4.01% |
| Float | 1.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.40 |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.51 |
Financial Efficiency
Return on equity (ROE) is -126.52% and return on invested capital (ROIC) is -67.99%.
| Return on Equity (ROE) | -126.52% |
| Return on Assets (ROA) | -62.88% |
| Return on Capital (ROIC) | -67.99% |
| Revenue Per Employee | $251,667 |
| Profits Per Employee | -$3.11M |
| Employee Count | 3 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 17.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.84% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -71.84% |
| 50-Day Moving Average | 2.92 |
| 200-Day Moving Average | 4.05 |
| Relative Strength Index (RSI) | 45.09 |
| Average Volume (20 Days) | 95,286 |
Short Selling Information
The latest short interest is 194,404, so 8.21% of the outstanding shares have been sold short.
| Short Interest | 194,404 |
| Short Previous Month | 310,304 |
| Short % of Shares Out | 8.21% |
| Short % of Float | 12.00% |
| Short Ratio (days to cover) | 0.21 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $755,000 and -$9.33 million in losses. Loss per share was -$5.66.
| Revenue | 755,000 |
| Gross Profit | 442,444 |
| Operating Income | -8.24M |
| Pretax Income | -9.02M |
| Net Income | -9.33M |
| EBITDA | -8.23M |
| EBIT | -8.24M |
| Loss Per Share | -$5.66 |
Full Income StatementBalance Sheet
The company has $90,854 in cash and $269,007 in debt, giving a net cash position of -$178,153 or -$0.08 per share.
| Cash & Cash Equivalents | 90,854 |
| Total Debt | 269,007 |
| Net Cash | -178,153 |
| Net Cash Per Share | -$0.08 |
| Equity (Book Value) | 13.39M |
| Book Value Per Share | 6.65 |
| Working Capital | -1.29M |
Full Balance SheetCash Flow
| Operating Cash Flow | -5.43M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.43M |
| FCF Per Share | -$2.30 |
Full Cash Flow StatementMargins
| Gross Margin | 58.60% |
| Operating Margin | -1,091.84% |
| Pretax Margin | -1,235.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -731.32% |